SCHEMBL16056962

SCHEMBL16056962

Cc1cc(-c2ccn(C(=O)O)c(=O)c2C)ccc1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 1/20 0.43
▸ EPHX1 P07099 1/20 0.40
▸ PPARG P37231 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ PDE3B Q13370 1/20 0.39
▸ PDE3A Q14432 1/20 0.39
▸ MMP2 P08253 1/20 0.37
▸ MMP3 P08254 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ MCL1 Q07820 1/20 0.37
▸ ADH5 P11766 2/20 0.36
▸ SLC2A1 P11166 1/20 0.36
▸ HSD17B1 P14061 1/20 0.35
▸ AKR1C3 P42330 3/20 0.35
▸ AKR1C2 P52895 3/20 0.35
▸ KDM4E B2RXH2 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ PTGS1 P23219 1/20 0.34
▸ EDNRB P24530 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16058506 0.91 MMP2 (0.41) ESR2MMP2MMP3AKR1C3AKR1C2
SCHEMBL16056873 0.91 MCL1 (0.42) PPARGPPARABRD4MCL1EDNRB
SCHEMBL14975270 0.89 KDM4E (0.39) BRD4KDM4EALDH1A1SMN1; SMN2PTGS1
SCHEMBL16057503 0.87 MCL1 (0.42) PPARGPPARABRD4MCL1EDNRB
SCHEMBL14975255 0.85 COMT (0.42) BRD4KDM4EPTGS1PDCD1CD274
SCHEMBL16058477 0.81 PGR (0.43) PPARGPPARAHSD17B1AKR1C2SMN1; SMN2
SCHEMBL16057154 0.81 RAB9A (0.42) ALDH1A1SMN1; SMN2
SCHEMBL16056806 0.80 LMNA (0.41) BRD4KDM4EALDH1A1SMN1; SMN2
SCHEMBL16058367 0.80 DHODH (0.43) PPARGPPARAALDH1A1
SCHEMBL16057665 0.79 PLA2G2A (0.43) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 ESR2 1888/4885EPHX1 222/4885PPARG 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback